Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Seres Therapeutics’ SER-155 Reduces Infection, GvHD In Animal Study
Seres Therapeutics Inc (NASDAQ: MCRB) will present preclinical findings at the European Bone Marrow Transplantation (EBMT) Annual Meeting.
Seres Therapeutics Highlights Presentation Of Preclinical Data On SER-155 At European Bone Marrow Transplantation Meeting Mar. 19 At 3:50 a.m. EDT
– Preclinical data demonstrate SER-155 reduces infection and Graft-versus-Host Disease –
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company,
Seres Therapeutics Earnings Perspective: Return On Capital Employed
Seres Therapeutics (NASDAQ:MCRB) brought in sales totaling $7.22 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 173.3%, resulting in a loss of $50.00 million.
Seres Therapeutics’ Oral Microbiome Candidate Shows Meaningful Improvements In Difficile Infection
Seres Therapeutics Inc (NASDAQ: MCRB) has
Seres Therapeutics Says New England Journal Of Medicine Publishes Data From ECOSPOR lll Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 In Recurrent C. Difficile Infection
Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced the publication in the New England Journal of Medicine (NEJM) of data from its Phase 3 ECOSPOR III study
Seres Posts Interim Microbiome Data Analysis From Failed Ulcerative Colitis Study
Seres Therapeutics Inc (NASDAQ: MCRB) announced